Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24082
Full metadata record
DC FieldValueLanguage
dc.contributor.authorColes, A. J.-
dc.contributor.authorBoyko, A. N.-
dc.contributor.authorCohen, J. A.-
dc.contributor.authorDe Seze, J.-
dc.contributor.authorFox, E. J.-
dc.contributor.authorHavrdova, E.-
dc.contributor.authorHartung, H. -P.-
dc.contributor.authorInshasi, J. S.-
dc.contributor.authorMcCombe, P.-
dc.contributor.authorSelmaj, K. W.-
dc.contributor.authorVermersch, P.-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorMargolin, D. H.-
dc.contributor.authorThangavelu, K.-
dc.contributor.authorRodriguez, C. E.-
dc.contributor.authorMontalban, X.-
dc.date.accessioned2017-08-04T13:45:21Z-
dc.date.available2017-08-04T13:45:21Z-
dc.date.issued2016-
dc.identifier.citationMULTIPLE SCLEROSIS JOURNAL, 22, p. 75-76 (Art N° 213)-
dc.identifier.issn1352-4585-
dc.identifier.urihttp://hdl.handle.net/1942/24082-
dc.description.sponsorshipSanofi Genzyme and Bayer HealthCare Pharmaceuticals. AJC: Consulting fees, lecture fees, and institutional grant support (Sanofi Genzyme). ANB: Consulting fees/participated in clinical trials (Bayer, Biogen, Merck Serono, Novartis, Sanofi-Aventis, Sanofi Genzyme, and Teva Pharmaceuticals). JAC: Consulting and/or speaking fees (Genentech, Novartis, Sanofi Genzyme); and compensation for serving as a journal editor, associate editor, or member of an editorial advisory board (Multiple Sclerosis Journal: Experimental, Translational and Clinical). EJF: Consulting and/or speaking fees, and grant/research support (Acorda, Bayer, Biogen, Chugai, Eli Lilly, EMD Serono, Genentech, Novartis, Opexa, Roche, Sanofi, Sanofi Genzyme, and Teva Pharmaceuticals). EH: Honoraria and grant support (Actelion, Biogen, Merck Serono, Novartis, Receptos, Roche, Sanofi Genzyme, and Teva) and is supported by Ministry of Education of Czech Republic. H-PH: Consulting and/or speaking fees (Bayer, Biogen, CSL Behring, Grifols, Merck Serono, Novartis, Roche, and Sanofi Genzyme). PM: Consulting and/or speaking fees (Biogen, Novartis, Sanofi-Aventis, and Teva Pharmaceuticals). KWS: Consulting and/or speaking fees (Biogen, Merck, Novartis, Roche, Sanofi Genzyme, and Synthon). PV: Consulting and/or speaking fees, and research support (Almirall, Bayer, Biogen, GlaxoSmithKline, Merck Serono, Novartis, Sanofi Genzyme, and Teva). BVW: Received research and travel grants, honoraria for MS-expert advice, and speakers fees (Bayer-Schering, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, and Teva). DHM, KT, and CER: Employees of Sanofi Genzyme. XM: Consulting and/or speaking fees (Almirall, Bayer, Biogen, EMD, Genentech, Geneuro, Merck, Neurotec, Novartis, Roche, Sanofi, Sanofi Genzyme, and Teva Pharmaceuticals).-
dc.language.isoen-
dc.publisherSAGE PUBLICATIONS LTD-
dc.titleAlemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateSEP 14-17, 2016-
local.bibliographicCitation.conferencename32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-
local.bibliographicCitation.conferenceplaceLondon, ENGLAND-
dc.identifier.epage76-
dc.identifier.spage75-
dc.identifier.volume22-
local.format.pages2-
local.bibliographicCitation.jcatM-
dc.description.notes[Coles, A. J.] Univ Cambridge, Sch Med, Cambridge, England. [Boyko, A. N.] Pirogov Russian Natl Res Univ, Moscow, Russia. [Boyko, A. N.] Usupov Hosp, Demyelinating Dis Ctr, Moscow, Russia. [Cohen, J. A.] Cleveland Clin, Cleveland, OH 44106 USA. [De Seze, J.] Univ Strasbourg, Strasbourg, France. [Fox, E. J.] Cent Texas Neurol Consultants, Round Rock, TX USA. [Havrdova, E.] Charles Univ Prague, Med Fac 1, Prague, Czech Republic. [Hartung, H. -P.] Heinrich Heine Univ, Dusseldorf, Germany. [Inshasi, J. S.] Rashid Hosp, Dubai, U Arab Emirates. [Inshasi, J. S.] Dubai Med Coll, Dubai, U Arab Emirates. [McCombe, P.] Univ Queensland, Brisbane, Qld, Australia. [Selmaj, K. W.] Med Univ Lodz, Lodz, Poland. [Vermersch, P.] Univ Lille Nord France, Lille, France. [Van Wijmeersch, B.] Univ Hasselt, Hasselt, Belgium. [Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E.] Sanofi Genzyme, Cambridge, MA USA. [Montalban, X.] MS Ctr Catalonia, Barcelona, Spain.-
local.publisher.placeLONDON-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.bibliographicCitation.artnr213-
dc.identifier.isi000383267200122-
item.accessRightsOpen Access-
item.fulltextWith Fulltext-
item.fullcitationColes, A. J.; Boyko, A. N.; Cohen, J. A.; De Seze, J.; Fox, E. J.; Havrdova, E.; Hartung, H. -P.; Inshasi, J. S.; McCombe, P.; Selmaj, K. W.; Vermersch, P.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E. & Montalban, X. (2016) Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).. In: MULTIPLE SCLEROSIS JOURNAL, 22, p. 75-76 (Art N° 213).-
item.contributorColes, A. J.-
item.contributorBoyko, A. N.-
item.contributorCohen, J. A.-
item.contributorDe Seze, J.-
item.contributorFox, E. J.-
item.contributorHavrdova, E.-
item.contributorHartung, H. -P.-
item.contributorInshasi, J. S.-
item.contributorMcCombe, P.-
item.contributorSelmaj, K. W.-
item.contributorVermersch, P.-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorMargolin, D. H.-
item.contributorThangavelu, K.-
item.contributorRodriguez, C. E.-
item.contributorMontalban, X.-
crisitem.journal.issn1352-4585-
crisitem.journal.eissn1477-0970-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Alemtuzumab provides durable improvements in clinical outcomes in treatment.pdfPeer-reviewed author version447.95 kBAdobe PDFView/Open
Show simple item record

WEB OF SCIENCETM
Citations

10
checked on Nov 20, 2025

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.